As a new type of foreign trade service provider driven by technological transformation and foreign trade business, HiSiaddi has built a "1+2+3+4=1" service system and can supply bile acid raw materials from multiple well-known original manufacturers. As a foreign trade enterprise with R&D capabilities and over a decade of market experience, HiSiaddi has rich expertise resolving product compliance issues through technological cooperation with manufacturers. Below is a case of bile acid compliance resolution delivered by HiSiaddi.
If you require consultation on bile acid product compliance issues, please contact HiSiaddi customer service.
The client is PharmaVision, a top-tier German pharmaceutical enterprise specializing in prescription-grade hepatobiliary medicines, sterile liposomal carriers and premium medical dietary supplements sold at high-end hospitals, pharmacies and medical aesthetic institutions across German-speaking regions including Germany, Switzerland and Austria. It enforces zero tolerance for compliance violations with stringent documentation and audit standards aligned with EP, USP, EU GMP, REACH regulations and EDQM sterility standards.
In April 2026, the client launched an annual procurement plan for 120 tons of pharmaceutical-grade ursodeoxycholic acid (UDCA) for mass production of a new generation of hepatobiliary repair capsules. During its first import customs clearance, dual compliance blockades were imposed by EU customs and EDQM, triggering three core compliance failures:
1. REACH regulation violations: The product lacked EU REACH registration (mandatory for annual volumes ≥1 ton) and lacked an Only Representative (OR) qualification, resulting in ECHA notification, port detention of goods and risk of return shipment plus fines equivalent to 10% of cargo value.
2. Missing CEP certificates: The client’s end formulations required EDQM Certificate of Suitability (CEP), yet the original supplier only provided domestic GMP certificates without CEP or DMF filings, preventing passage of German pharmaceutical regulatory audits.
3. Broken animal-origin traceability: UDCA was bovine bile-extracted, requiring full two-way traceability from slaughterhouses → bile collection → extraction workshops → finished goods under EU regulations. The original supplier lacked veterinary quarantine certificates, traceability codes and viral inactivation validation reports, classifying the product as "high-risk animal-origin goods" and prohibiting entry.
The original supplier lacked capacity to resolve compliance issues, exposing the client to production line raw material shortages, delayed delivery of a 15 million Euro order, postponed product launches and reputational damage. The client urgently entrusted HiSiaddi with a 7-day deadline to resolve all three compliance obstacles, complete customs clearance and resume supply.
1. Missing REACH registration and OR qualification: Revoked EU chemical market access permit EU REACH regulation mandates that non-EU enterprises exporting single-component chemicals in annual volumes ≥1 ton complete REACH registration and appoint an EU-based Only Representative (OR) responsible for compliance declarations, data submission, risk assessment and official communications. The original supplier held no REACH registration, no OR cooperation agreement and no SVHC Substance of Very High Concern testing reports, directly violating EU regulations and prompting ECHA to detain goods and block customs clearance.
2. Blank CEP certificates and DMF filings: Unmet core European pharmacopoeia audit threshold German pharmaceutical enterprises producing end formulations must pass EDQM audits requiring raw material CEP certificates (certifying EP pharmacopoeia compliance), FDA DMF filings (validating compliant production processes and quality control) and full English COAs aligned with EP/USP standards. The original supplier only held domestic GMP certificates without CEP, DMF or EU-standard English COAs, blocking regulatory audits and end-product market launches.
3. Broken full-chain animal-origin traceability: Violation of EU biosafety red lines Bovine bile-derived UDCA qualifies as animal-origin API subject to EU mandatory requirements: ① Veterinary quarantine certificates from slaughterhouses confirming freedom from BSE and foot-and-mouth disease; ② Full temperature control records for bile collection and transport; ③ Viral inactivation validation reports from extraction workshops; ④ Unique finished goods traceability codes linking to individual livestock; ⑤ Animal-origin contamination-free declarations. The original supplier lacked complete traceability systems, quarantine certificates, inactivation validation and traceability codes, resulting in classification as "extremely high biosafety risk" with entry prohibited and mandatory return shipment deadlines.
HiSiaddi immediately assembled a cross-functional team including EU REACH registrars, EDQM certification specialists, animal-origin traceability experts, customs clearance consultants and pharmaceutical-grade bile acid technical specialists with clear task allocation and 7-day delivery deadlines for full-cycle compliance rectification.
Compliance resource alignment: Partnered with a local German OR institution holding pharmaceutical chemical registration qualifications to launch expedited REACH registration procedures. Data collation and submission: Compiled full UDCA physicochemical, toxicological and production process datasets alongside SVHC testing reports (all 219 high-concern substances tested negative), submitted to ECHA via the OR institution. Registration approval: Expedited processing leveraging complete datasets delivered REACH registration acceptance numbers and OR qualification certificates within 2 days, prompting ECHA to lift goods detention and authorize customs clearance. Long-term compliance guarantee: Signed an annual compliance agreement with the OR institution covering ongoing registration maintenance, data updates and official communications to sustain permanent compliance.
Compliant manufacturer screening: Coordinated Zhongshan Bailing Bio, China’s sole UDCA manufacturer holding both CEP and DMF qualifications, to launch certificate reuse and batch binding procedures. Document review and translation: Compiled the manufacturer’s EDQM-issued CEP certificate (EP 10.0 compliant), FDA DMF filing documents (Filing No.027153), full EP/USP-compliant English COAs (99.9% purity, total impurities ≤0.1%) and EU GMP-audited production records. Batch binding confirmation: Linked the client’s order batches to the manufacturer’s CEP/DMF filing batches with official batch conformity statements to guarantee audit traceability. Document delivery: Full sets of English compliance documentation delivered within 3 days, passing preliminary German pharmaceutical regulatory reviews to satisfy mandatory CEP/DMF requirements.
Upstream traceability alignment: Coordinated the manufacturer’s EU-qualified slaughterhouse partners with veterinary quarantine accreditations to retrieve batch-specific bovine bile records including veterinary quarantine certificates, slaughter logs and livestock identification numbers. Complete temperature control records: Supplemented full cold-chain temperature data (2–8℃ constant temperature, fully traceable) covering bile collection, cold transport and factory warehousing. Viral inactivation validation: Provided the manufacturer’s UDCA production viral inactivation validation reports (121℃/30min validated to effectively inactivate prions and viruses). Unique traceability code assignment: Allocated exclusive traceability codes to each finished goods batch, cross-referencing slaughterhouse records, bile batches, production lots and testing reports to enable two-way traceability from finished goods to individual livestock. Compliance declaration issuance: Issued animal-origin contamination-free declarations and statements confirming alignment with EU animal-origin product safety standards, passing customs biosafety inspections.
Full document submission: Submitted REACH registration acceptance numbers, OR qualification certificates, CEP certificates, DMF filings, English COAs, animal-origin traceability files, quarantine certificates, inactivation reports and traceability codes to German customs and EDQM. Online inquiry resolution: HiSiaddi compliance specialists coordinated online communications with customs and regulatory authorities to resolve data inquiries and confirm full compliance, securing customs clearance release within 1 day. Pre-audit simulation approval: Assisted the client with EDQM pre-audit simulations, confirming complete traceable documentation with zero compliance defects to guarantee 100% pass rates for formal regulatory audits.
1. 100% resolution of three core compliance challenges
· REACH compliance: Completed registration and OR qualification; ECHA lifted detention and authorized customs clearance.
· CEP/DMF compliance: Full certificate and documentation packages available, passing preliminary German regulatory audits.
· Animal-origin traceability: Full-chain traceability system established, passing biosafety inspections.
1. Goods released and production resumed The detained 120 tons of UDCA cleared customs and delivered to the client’s factory, fully restoring production line capacity. The 15 million Euro order was delivered on schedule, with end formulations passing EDQM audits and launching as scheduled.
2. Deepened long-term compliance cooperation The client designated HiSiaddi as its exclusive Chinese partner for bile acid raw material supply and compliance services. All subsequent bile acid procurement fully entrusts HiSiaddi with compliance processing, documentation review, customs clearance and audit support, generating stable annual procurement volume of 15 million Euros.
Client Feedback: "HiSiaddi’s team are genuine experts in EU high-end pharmaceutical compliance. They efficiently resolved three core compliance hurdles covering REACH, CEP and traceability within 7 days with exceptional professionalism, speed and reliability, fully matching the stringent compliance requirements of our German pharmaceutical enterprise and serving as our most trusted compliance backup."
Overseas mid-to-high-end pharmaceutical enterprises purchasing bile acids (especially animal-origin pharmaceutical-grade UDCA) commonly face core compliance pain points including missing REACH registration, blank CEP/DMF certificates and broken animal-origin traceability. Most ordinary manufacturers only supply basic raw materials without EU compliance qualifications, dedicated compliance teams or capacity to respond to EDQM/ECHA audits, which often trigger goods detention, return shipment fines, audit failures, delayed product launches and massive financial losses.
HiSiaddi’s core value lies in comprehensive expertise covering EU pharmaceutical compliance systems, access to CEP/DMF qualified manufacturers, capacity to establish full animal-origin traceability chains, rapid implementation execution and full-cycle audit support. Within 7 days, we fully remedy three major compliance gaps, deliver complete English compliance documentation and build full-chain traceability systems to guarantee customs clearance and audit passage. We help clients break through compliance bottlenecks, secure stable raw material supply, accelerate product launches and consolidate market position in Europe’s high-end pharmaceutical sector.
If you require consultation on bile acid product compliance issues, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
